Kobe Biocluster Looks To Support Partners, Novel Technology
This article was originally published in Start Up
The Foundation for Biomedical Research and Innovation co-ordinates Kobe’s life sciences activities and heads up the Biomedical Kansai network, Japan’s largest biocluster. It is seeking international life sciences investors and partners for licensing, co-development and funding options.
You may also be interested in...
Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.
A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.
Speakers from the legal, corporate and contract research sectors discussed the fast-moving changes that are impacting the legal and regulatory aspects of doing business in China at the recent AusBiotech conference in Melbourne, providing a broad range of advice for Australian and other pharma and biotech companies wanting to enter the rapidly expanding Chinese life sciences market.